Related Experiment Video
Updated: Jul 16, 2026
09:15
In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Vascular disrupting agents in clinical development
1Department of Medical Oncology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands.
British Journal of Cancer
|March 22, 2007
Summary
Vascular disrupting agents (VDAs) offer a novel anticancer therapy by targeting established tumor vasculature, causing blood flow shutdown and tumor necrosis. Clinical studies are reviewing VDA efficacy and future development for cancer treatment.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Tumor growth relies on oxygen and nutrients supplied by tumor vasculature.
- Targeting tumor vasculature is a key strategy in anticancer therapy.
- Vascular disrupting agents (VDAs) represent a distinct class of anticancer drugs.
Purpose of the Study:
- To discuss the mechanism of action of vascular disrupting agents (VDAs).
- To review preclinical and clinical study results of VDAs.
- To provide considerations for the future development of VDAs.
Main Methods:
- Review of preclinical studies on VDAs.
- Analysis of clinical trial data for VDAs.
- Discussion of VDA mechanisms of action.
Main Results:
- VDAs target established tumor vasculature, causing acute blood flow shutdown.
- This shutdown leads to selective tumor necrosis.
- Ongoing clinical studies are evaluating VDA effectiveness.
Conclusions:
- VDAs are a promising therapeutic strategy targeting tumor vasculature.
- Further clinical evaluation is necessary to optimize VDA development.
- VDAs offer a novel approach to anticancer therapy.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...